Aesthetic Clinic Advertising: An Evolving Regulatory Landscape
The regulation of aesthetic clinic advertising has intensified significantly following the Health and Care Act 2022 and the recommendations of the Paterson Inquiry and HEE review. The sector, which includes surgical and non-surgical cosmetic procedures, sits at the intersection of healthcare regulation, consumer protection law, and advertising standards. Clinics promoting injectables, laser treatments, body contouring, and surgical procedures must navigate overlapping obligations from multiple regulatory bodies.
The ASA enforces CAP Code Section 15 rigorously in this sector. Aesthetic clinic advertising has been one of the ASA's highest-priority proactive monitoring areas since 2012, and the volume of upheld rulings against aesthetic providers remains high. Non-compliance is not merely a reputational risk — it can trigger referral to the CQC, professional regulatory bodies, and in the case of prescription medicine advertising, the MHRA.
The rise of social media marketing and influencer partnerships has created additional compliance complexity. Content produced by clinic employees, brand ambassadors, and paid influencers is all within the ASA's scope. Clinics are responsible for ensuring that any advertising they commission or benefit from meets regulatory standards, regardless of who produces or posts it.
Important: LearnedCare Sentinel is a decision-support tool only. It does not provide legal advice. Human review by a qualified compliance professional remains required before any content is published. Regulatory decisions are the sole responsibility of the user's organisation.
Critical Compliance Areas for Aesthetic Clinics
Under-18 Restrictions
The Health and Care Act 2022 prohibits the performance of certain non-surgical cosmetic procedures on persons under 18. Advertising for these procedures must not target under-18 audiences. CAP Code Section 15.2 explicitly prohibits advertising for cosmetic interventions that is likely to be seen by under-18s, and requires that advertising not normalise cosmetic procedures for younger audiences. This includes social media advertising where audience age targeting must be actively managed.
Prescription Injectable Advertising
Botulinum toxin products (Botox, Bocouture, etc.) are prescription-only medicines. Consumer-facing advertising that names or describes these products may constitute unlawful DTC prescription medicine advertising under MHRA regulations. Aesthetic clinics must carefully structure their injectable treatment advertising to promote the treatment service rather than the specific POM being used.
Non-Trivialisation Requirement
All advertising for cosmetic interventions must not trivialise the procedure or the decision to undergo it. This means avoiding language that minimises recovery time, risk, or the physical and psychological significance of the intervention. Terms such as 'quick and easy', 'non-invasive' (where not accurate), or 'no side effects' may breach Section 15.1 unless they accurately describe the procedure and are supported by evidence.
Before-and-After Imagery
Before-and-after images must accurately represent achievable outcomes. Images must not be digitally enhanced, must not rely on flattering lighting or pose differences to create the appearance of improvement, and must disclose relevant factors that may have contributed to the result. The ASA has upheld multiple complaints against aesthetic providers for misleading before-and-after imagery.
Influencer and Social Media Compliance
All paid or incentivised social media content promoting aesthetic treatments must be disclosed as advertising. This includes complimentary treatments, affiliate arrangements, and any commercial relationship. The clinic is responsible for ensuring that influencer content complies with CAP Code rules, including the prohibition on promoting POM treatments by name and the under-18 audience restrictions.
LearnedCare Sentinel for Aesthetic Clinic Compliance
LearnedCare Sentinel applies CAP Code Section 15, MHRA injectable advertising rules, and under-18 restriction frameworks when scanning aesthetic clinic content. The platform identifies specific language patterns, claim types, and structural features that indicate compliance risk in the context of cosmetic procedure advertising.
For aesthetic groups and clinic chains, the Professional and Governance plans support centralised compliance review with multi-user access. Marketing managers can submit content, and a compliance lead or designated reviewer approves before publication. The full audit trail documents every review decision — an essential safeguard given the ASA's proactive monitoring in this sector.
The platform's patient safety communications review adds an additional lens for content directed at potentially vulnerable patient groups — flagging communication patterns that may exploit body image concerns or create undue pressure to proceed with treatment.
Related Compliance Guidance
Compliance Hub
Full overview of UK healthcare compliance
ASA Compliance
CAP Code Section 15 in practice
MHRA Compliance
Prescription medicine advertising rules
CAP Code
Non-broadcast advertising standards
Dental Marketing
GDC-aligned dental advertising guidance
Governance Workflow
Structured pre-publication review